Showing 201 - 220 results of 77,706 for search '(( 50 ((we decrease) OR (((nn decrease) OR (a decrease)))) ) OR ( a e decrease ))', query time: 1.19s Refine Results
  1. 201
  2. 202
  3. 203
  4. 204
  5. 205

    Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  6. 206

    Protocol measures. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  7. 207

    Cry variables. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  8. 208
  9. 209
  10. 210
  11. 211
  12. 212
  13. 213

    Simulated effects of increased pCREB combined with decreased pCaMKIIα on bistability. by Yili Zhang (540283)

    Published 2022
    “…<p>(A1) Modification of model. Increased basal phosphorylation of CREB <i>k</i><sub><i>basalp_creb</i></sub>, concurrent with decreased basal phosphorylation of CaMKIIα <i>k</i><sub><i>basalp_CaMKII</i></sub>, in the absence of the effects of MeCP2/HDAC2/Sin3a (red) ([<i>E</i><sub><i>comp</i></sub>] = 0; [<i>E</i><sub><i>MeCP2</i></sub>] = 0). …”
  14. 214

    CDDO-Me radioprotection decreases with progressive oncogenic manipulations in HBECs and in a matched NSCLC line. by Mariam El-Ashmawy (678638)

    Published 2014
    “…(D) HBEC 30KT are protected by CDDO-Me. (E) HCC 4017, a NSCLC isolated from the same patient from which HBEC 30KT was derived, are unprotected by CDDO-Me. …”
  15. 215
  16. 216
  17. 217
  18. 218
  19. 219
  20. 220